Results are presented as means S.D. cell proliferation and myotube formation in malignancy conditioned media. In summary, PN significantly suppressed mutated KRAS-driven cell growth and reserved muscle mass cell function. Based on the current study, PN could be considered as a encouraging starting point for the development of a nature-derived drug against KRAS-mutated CRC progression. Mill [9], protopine from [10], Paris saponin VII from [11] and protein hydrolysates from Fenugreek ([12] suppressed the proliferation and induced apoptosis of CRC cells. Additionally, rosemary (germinated soybeans suppressed mutated KRAS-driven APY29 CRC via the RAS/ERK pathway [14]. produced on germinated brown rice increased the sensitivity of Cetuximab to inhibit KRAS-CRC progression both in vitro and in vivo [15]. Although the two natural compounds have anti-CRC activities, more medicinal substances are needed to target the notorious and drug-resistant nature of mutated KRAS-driven CRC. Morning glory (is the main constitute of the approved drug, DA-9701 (Motilitone) [20]. DA-9701 is usually a botanical drug for treating functional dyspepsia and composed of the seed of and tuber. Therefore, we anticipated its security on human and can be adapted for therapies in a relatively short timeframe if confirmed its efficiency. In view of its anticancer effects, we considered the active compound of semen (PN) may inhibit the proliferation and progression of mutated KRAS-driven CRC without inducing severe side effects. In addition to the suppressive effect of PN on CRCs, we evaluated the effect of compound PN on muscle mass cell function. During the course of CRC, cachexia, a complex syndrome showing severe muscle weight loss, is usually often APY29 accompanied with APY29 CRC progression and worsened treatment therapies [21,22,23]. Therefore, treating APY29 cachexia becomes an important combinational therapy in the treatment of CRCs. We mimicked cancer-associated environment with conditioned media and evaluated the effect of PN on muscle cells. In the present study, the anticancer activity of PN was investigated Rabbit Polyclonal to ABHD8 by examining its anti-proliferation and clonogenic features in five different CRC cell models. Cell cycle and apoptotic analyses were performed, and the changes in RAS/ERK and AKT/mTOR pathways were investigated. Finally, we assessed the effect of the compound PN on muscle cell proliferation and function. 2. Results and Discussion 2.1. PN Suppressed Colorectal Cancer Cell Progress To investigate the anti-proliferative effects of PN on mutated KRAS-driven CRC, KRAS mutated SW480 and HCT116 cells as well as KRAS-wild type (WT) HT29 and WiDr were evaluated. Cells were treated with PN at 0, 0.1, 0.5, 1, 2, or 4 g/mL and incubated for 48 or 72 h in triplicate. Cetuximab which has been used to treat mutated KRAS-driven CRCs was used as a control. Figure 1A summarized the proliferation profiles. PN inhibited cell growth in a concentration dependent manner in mutated KRAS-driven cell lines at 48 and 72 h. At 72 h, SW480 viability was decreased to 41.6 1.0% when treated with PN at 2 g/mL and to 26.0 4.5% when treated with 4 g/mL PN. When compared to control drug of Cetuximab, PN showed higher suppressive effect from 2 g/mL concentration. Data also indicated that KRAS mutated cell lines responded more sensitively on PN treatment compared to KRAS wild type cells of HT-29 and WiDr. In KRAS wild type cells, PN treatment did not show statistical decrease on proliferation at 48 h. The IC50 values of KRAS mutated cells at 72 h are 1.74 and 2.78 g/mL on SW480 and HCT116 cells, whereas they are 4.14 and 4.46 g/mL on KRAS WT cells of HT29 and WiDr cells. IC50 values of KRAS mutated cells are relatively low compared to other natural extract such as pogostone (HCT116: 18.7 1.93 g/mL) [24]. Open in a separate window Figure 1 (A) PN suppressive effect on KRAS-mutated colorectal cancer cells of SW480 (KRASG12V) and HCT116 (KRASG13D), and KRAS-wild types CRCs of HCT116 and WiDr. Cells were treated for 48 and 72 h under PN treatment (0, 0.1, 0.5, 1, 2 and 4 g/mL) and Cetuximab (30 g/mL). IC50 values are calculated. Results are presented as means S.D. of three independent experiments. * 0.05, ** 0.01, *** 0.001. (B) Representative colorectal cancer cell images under PN treatment (0, 0.5, 1 and APY29 4 g/mL). Blue represents the DAPI-stained cell nuclei,.